Status:
ACTIVE_NOT_RECRUITING
Intervention Study Based on Real-world Data to Improve Quality of Life After Breast Cancer Treatment, the REBECCA-2 Study
Lead Sponsor:
Helse Stavanger HF
Conditions:
Cancer Related Fatigue
Eligibility:
FEMALE
19-80 years
Phase:
NA
Brief Summary
The overall objective of the REBECCA studies at Stavanger University Hospital (SUH) is to improve the QoL of patients affected by cancer-related fatigue during and after end of treatment, by collectin...
Detailed Description
1. Background: Clinical research is undergoing revolutionary changes by use of electronic patient records (EHR), digital registers and smartphones. The widespread use of portable devices have led ...
Eligibility Criteria
Inclusion
- Participants have had histologically proven M0 breast cancer (stage 0-II) breast cancer that require neoadjuvant or adjuvant chemo- and/or radio-therapy at least and no more than 3 months pre-study initiation.
- Age between 19 and 80 years
- Have increased life expectancy beyond the initial 3 months post-treatment.
- Have the ability to understand protocol, participate in testing and willingness to sign a written informed consent.
- Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.
Exclusion
- Male breast cancer patients
- Patients that are not willing to sign an informed consent form
- A previous cancer diagnosis (excluding skin cancers treated by surgery only)
- Patients previously treated by any form of chemo/radiotherapy.
Key Trial Info
Start Date :
November 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2025
Estimated Enrollment :
81 Patients enrolled
Trial Details
Trial ID
NCT06120595
Start Date
November 1 2022
End Date
May 1 2025
Last Update
June 27 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stavanger University Hospital
Stavanger, Rogaland, Norway, 4067